Norethisterone with mestranol
Brand names: Norinyl-1
This is a fixed-dose combined oral contraceptive pairing the progestogen norethisterone with the oestrogen mestranol, used for contraception and cycle control.
Adult dose
Dose adjustments
No renal dose adjustment is stated in the SPC; kidney disease is listed among conditions in which women taking oral contraceptives require careful observation (§4.4).
Acute or severe chronic liver disease, including liver tumours, Dubin-Johnson or Rotor syndrome, is a contraindication (§4.3); progestogen oestrogen preparations should be used with caution in patients with a history of hepatic dysfunction or hypertension (§4.4). No dose adjustment is given.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substances or to any of the excipients
- History of confirmed venous thromboembolic disease (VTE), family history of idiopathic VTE and other known risk factors of VTE
- Thrombophlebitis, cerebrovascular disorders, coronary artery disease, myocardial infarction, angina, hyperlipidaemia or a history of these conditions
- Acute or severe chronic liver disease, including liver tumours, Dubin-Johnson or Rotor syndrome
- History during pregnancy of idiopathic jaundice, severe pruritus or pemphigoid gestationis
- Known or suspected breast or genital cancer; known or suspected oestrogen-dependent neoplasia
- Undiagnosed abnormal vaginal bleeding
- A history of migraines classified as classical focal or crescendo
- Pregnancy
- Concomitant use of medicinal products containing ombitasvir/paritaprevir/ritonavir and/or dasabuvir
Side effects
- Slight nausea at first, weight gain or breast discomfort, which soon disappear
- Gastro-intestinal symptoms, changes in libido and appetite, headache, exacerbation of existing uterine fibroid disease, depression, and changes in carbohydrate, lipid and vitamin metabolism
- Spotting or bleeding during the first few cycles; menstrual bleeding usually becomes light and occasionally there may be no bleeding during the tablet-free days
- Hypertension (usually reversible on discontinuing treatment) in a small percentage of women
- Venous thromboembolism - all combined hormonal contraceptives increase the risk; norethisterone-containing products are associated with the lowest risk, and the risk is highest in the first ever year of use (§4.4)
- Arterial thrombosis risk increases with age and is aggravated by cigarette smoking; benign and malignant liver tumours and gall bladder disease have been associated with oral contraceptive use (§4.4)
Interactions
- St John's wort (Hypericum perforatum) - should not be taken concomitantly: potential loss of contraceptive effect
- Certain sedatives, antibiotics, anti-epileptic and anti-arthritic drugs - may modify the metabolism of Norinyl-1 and reduce effectiveness; use mechanical contraceptives as well
- Ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin - contraindicated (risk of ALT elevations); switch to an alternative contraceptive method before starting and Norinyl-1 can be restarted 2 weeks after completing that regimen
- Laboratory tests - results (biochemical markers of thyroid and liver function; plasma levels of carrier proteins, triglycerides, coagulation and fibrinolysis factors) may be influenced by oestrogen-containing oral contraceptives
Monitoring
- Personal and family medical history before starting and at regular intervals; measure blood pressure and, if judged appropriate by the clinician, breast, abdominal and pelvic examination including cervical cytology
- Regular surveillance for thromboembolism and cardiovascular conditions
- Careful observation in women with breast nodules, fibrocystic breast disease, uterine fibroids, a history of severe depressive states, varicose veins, sickle-cell anaemia, diabetes (glucose tolerance may decrease), hypertension, cardiovascular disease, migraine, epilepsy, asthma and the other conditions listed in §4.4
- Discontinue if there is loss of vision or ocular changes, onset or aggravation of migraine, or a new recurrent, persistent or severe headache
- Right upper quadrant mass or tenderness or acute abdomen - consider a liver tumour
Clinical monograph
How it works
Mestranol (a prodrug converted to ethinylestradiol) and norethisterone together suppress gonadotrophin release to inhibit ovulation, while also thickening cervical mucus and altering the endometrium.
Prescribing in practice
- As a combined oestrogen-containing preparation it raises the risk of venous and arterial thromboembolism and is contraindicated where this risk is high, such as migraine with aura, established cardiovascular disease, or smoking in older women.
- Efficacy may be reduced by enzyme-inducing drugs, and the woman should be assessed against UK Medical Eligibility Criteria before starting.
- Counsel on what to do about missed pills and that additional precautions may be needed in certain situations.
Monitoring
Check blood pressure and review thrombotic and cardiovascular risk factors before starting and periodically during use.
Counselling the patient
- Take it regularly and follow the missed-pill instructions to keep contraceptive cover.
- Stop and seek urgent care for severe leg pain or swelling, chest pain, breathlessness, or sudden severe headache or visual change.
- Tell your clinician about migraines with aura, smoking, and any new medicines.
Evidence & guidelines
Combined oral contraceptives are prescribed in line with the UK Medical Eligibility Criteria and Faculty of Sexual and Reproductive Healthcare guidance.
Reference: FSRH; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21